Renal Cell Carcinoma

Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.

Patients with advanced renal cell carcinoma who have progressed on cabozantinib (Cabometyx) and nivolumab (Opdivo), now have a promising new treatment option.

Sue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.

The combination of lenvatinib (Lenvima) and everolimus (Afinitor) has been approved by the FDA as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogeneic therapy.

Nivolumab (Opdivo) produced exceptional responses in patients with renal cell carcinoma, which may pave the way for further treatment breakthroughs, according to Mark Ball, MD.

The FDA has approved cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.

Advances in kidney cancer deal much more in surgery, rather than treatment options, according to Alexander Kutikov, MD, FACS.

The second interim analysis of the phase III METEOR trial has revealed a statistically significant improvement in overall survival (OS) with cabozantinib (Cometriq) versus everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following progression on one prior therapy, according to a statement from the drug's developer, Exelixis.

Cabozantinib (Cometriq) has receieved a priority review designation from the FDA for patients with advanced renal cell carcinoma (RCC) following progression on one prior therapy, according to Exelixis, the drug's developer.

The combination of lenvatinib (Lenvima) and everolimus (Afinitor) has been given a priority review status by the FDA as a treatment for patients with metastatic renal cell carcinoma (RCC) following one prior VEGF-targeted therapy.

Srinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.

Patients with renal cell carcinoma (RCC) who express higher entropy, a measure of T-cell diversity, could translate to a more favorable prognosis

Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.

Novel clinical trials are currently assessing the combination of VEGF-targeted agents and immune checkpoint inhibitors as frontline therapies for patients with metastatic renal cell carcinoma (RCC).

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC.

Combining a selective class I oral histone deactylase (HDAC) inhibitor with high-dose interleukin (IL)-2 may boost the latter's antitumor effect in renal cell carcinoma (RCC).

Nivolumab shows consistent survival benefit across subgroups as a second-line treatment for renal cell carcinoma (RCC), according to data from an analysis of the phase III CheckMate-025 trial.

In a comparison study, cabozantinib significantly boosted progression-free survival (PFS) against everolimus in patients with renal cell carcinoma (RCC) regardless of metastases degree, type, number of prior treatments, or patient risk status.

The programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors "are going to disrupt the current treatment paradigm and will likely be the backbone of combination therapy," said Hans J. Hammers, MD, PhD.

The FDA has received a new drug application for cabozantinib (Cometriq) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.

The FDA has approved nivolumab (Opdivo) as a treatment for patients with metastatic renal cell carcinoma following prior treatment with an anti-angiogenic therapy.

The treatment paradigm for renal cell carcinoma (RCC) could undergo major changes in the future due to several novel therapies in the works for regulatory approval and checkpoint inhibitors, vaccines, recombinant T-cell receptors, and bi-specific T-cell engagers.

The PD-1 inhibitor nivolumab (Opdivo) has gained a priority review status from the FDA as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogenic therapy.

Dr. Robert Figlin talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.

Unspecific immunotherapy with interleukin-2 (IL-2) and interferon-alpha was regarded as the first effective therapy in patients with RCC, leading to remarkable clinical benefit in attaining durable complete responses.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director, Urologic Oncology, University of Chicago Medicine, discusses the potential of immunotherapy on the treatment of renal cell carcinoma.

The risk of death for patients with advanced renal cell carcinoma (RCC) was reduced by 27% with nivolumab (Opdivo) versus everolimus (Afinitor), and overall survival (OS) was improved by 5.4 months.

The PD-1 inhibitor immunotherapy Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

Cabozantinib (Cometriq) was given a breakthrough therapy designation by the FDA for the treatment of patients who have advanced renal cell carcinoma (RCC), following one prior therapy.

Lenvatinib (Lenvima) was recently granted a breakthrough therapy designation by the FDA as a potential treatment for patients with advanced renal cell carcinoma (RCC) who have received a VEGF-targeted therapy.